WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 28-May-2015 (Data received as of 22-May-2015)
Next overall update July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Economy in transition GNI / capita (US$): 13'8601 Infant (under 12 months) mortality rate: 92
GDP / capita (US$): 24'1201 Child (under 5 years) mortality rate: 102

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 142'468  142'834  143'170  143'438  143'618  146'763  148'149  138'536 
Births 1'677  1'686  1'690  1'688  1'679  1'337  2'002  2'280 
Surviving infants 1'661  1'670  1'674  1'672  1'663  1'311  1'957  2'217 
Pop. less than 5 years 8'385  8'321  8'228  8'120  8'005  6'465  11'545  10'668 
Pop. less than 15 years 22'993  22'551  22'105  21'715  21'429  26'712  34'007  30'007 
Female 15-49 years 35'504  36'045  36'643  37'231  37'759  39'663  35'927  36'661 

Number of reported case

(Click for retrospective incidence data for Russian Federation (the))
Diphtheria 771  1'211 
Japanese encephalitis
Measles 4'711  2'339  2'123  629  129  4'800  18'370 
Mumps 267  282  394  406  510  40'976 
Pertussis 4'705  4'510  7'220  4'733  4'795  29'983  24'960 
Polio* 14 
Rubella 72  233  1'003  349  547  457'378 
Rubella (CRS) 11 
Tetanus (neonatal)
Tetanus (total)** 11  21  13  33 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Russian Federation (the))
Vaccine year result method % card seen                                                
BCG          96  96  96  95  96  96 
DTP1          97 
DTP3          97  97  97  97  97  96 
HepB_BD         
HepB3          97  97  97  97  97 
Hib3          90 
JapEnc         
MCV          98  98  98  98  98  97 
MCV2          97  97  97  97  97 
PCV1         
PCV3         
Pol3          97  98  98  98  98  97 
Rota1         
Rota_last         
Rubella1          98  98  98  99  98 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Russian Federation (the))
BCG 96  96  95  96  96 
DTP1 97  97  97  97  97 
DTP3 97  97  97  97  96 
HepB3 97  97  97  97 
HepB_BD
Hib3 18  18 
MCV 98  98  98  98  97 
MCV2 97  97  97  97  92 
PCV3
Pol3 98  98  97  98  97 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 3 days; 7, 14 years; Yes
DT 3, 4.5 months; 1 year; Yes
DTwP 3, 4.5, 6, 18 months; Yes
DTwPHep 6 months; Yes
Dip + 10 years; Yes
HIB 3, 4.5, 6, 18 months; Yes
HPV 13-14 years; No
HepA 20, 26 months; No
HepB_Adult 1st contact; +1, +6 months; Yes
HepB_Pediatric 1 day; 1, 2, 6 months; Yes
IPV 3, 4.5 months; Yes
Influenza_Adult >= 60 years; Pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric 6 months to 7 years; Yes and children with chronic diseases
MM 12 months; 6 years; Yes
MMR 12 months; 6 years; No
Measles 12 months; 6, 18-35 years; Yes
Mumps 12 months; 6 years; Yes
OPV 6, 18, 20 months; 14 years; Yes
Pneumo_conj 2, 4.5, 15 months; Yes
Rubella 12 months; 6, 18-25 years; Yes
Td 6-7, 14 years; +10 years; Yes
Varicella 12 months; No

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number             83 

System performance

Total Nº districts in country number   83  83  83  83  83  83 
Nº districts with DTP3 coverage >=80% number 83  83  83  83  83  83  83 
% of districts with DTP3 coverage >=80% From 0 to 100%   100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 83  83  83  83  83  83  83 
% of districts with MCV1 coverage >=95% From 0 to 100%   100  100  100  100  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  Yes  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No    No  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.